Targeting SETD2 in Cancer therapy: Structure, biological functions, and inhibitor development

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• SET domain-containing protein 2 (SETD2) is the sole enzyme catalyzing histone H3 trimethylation at lysine 36 (H3K36me3).
• SETD2 is essential for DNA repair, gene replication, transcription, and maintaining genome stability.
• Mutations in SETD2, particularly in its AWS-SET-PostSET domains, are linked to tumorigenesis and disease progression due to aberrant H3K36me3 levels.

Purpose of the Study:

• To review the domains, functions, and cancer-related roles of SETD2 and its family proteins.
• To elucidate the mechanisms of existing SETD2 inhibitors and their structure-activity relationships (SARs).
• To provide recommendations for the design of novel SETD2 inhibitors for cancer therapy.

Main Methods:

• Literature review of SETD2 protein domains, functions, and involvement in cancer.
• Analysis of existing SETD2 inhibitors, focusing on methylindole and sinefungin analog scaffolds.
• Examination of SARs and structural mechanisms of SETD2 inhibition, including key amino acid interactions.

Main Results:

• SETD2's critical role in DNA repair and genome stability is highlighted.
• Mutations in SETD2's functional domains are implicated in cancer development.
• Key inhibitor scaffolds and their SARs are summarized, emphasizing the importance of specific structural features for binding.

Conclusions:

• SETD2 is a significant target for cancer diagnosis and therapy.
• Understanding SETD2 inhibitor SARs is vital for developing effective drugs.
• Recommendations for designing novel SETD2 inhibitors are provided, focusing on structural features like rigid conformations.